PlaqueTec Ltd.

PlaqueTec Ltd. is revolutionizing the fight against atherosclerosis with their novel approach to understanding coronary artery disease (CAD). Their slogan, "Opening a new frontier in the fight against atherosclerosis," encapsulates their mission. CAD, a leading global cause of death, has been limited by one-size-fits-all treatments. However, PlaqueTec aims to change this narrative with their proprietary technology and data analysis platform. Founded in 2008 and based in the United Kingdom, the company recently secured a significant £6.40M in a Venture Round investment on 30 April 2024. This investment was led by the Future Fund and Lord Moynihan. Their focus on developing precision medicine through a deeper understanding of patient endotypes holds the potential to revolutionize drug development and treatment efficacy. PlaqueTec's pursuit of uncovering potential biomarkers of coronary vascular function and plaque progression signifies a promising shift towards tailored treatments. This approach not only has the potential to reduce clinical trial sizes and costs but also increase success rates, ultimately improving patient outcomes. In the Health Care sector, PlaqueTec's innovative strides offer a glimpse into the future of personalized medicine and targeted interventions in the fight against CAD.